Vascular Nano-Delivery Using Tropism and Targeting
Vladimir R. Muzykantov, MD, PhD | Founding Co-Director, CT3N at UPenn
Register
Email:
Phone:
Toggle navigation
Home
Services
ADC Linker Development
Enzyme Cleavable Linker
Cathepsin B Cleavable Linker
Phosphatase Cleavable Linker
β-Glucuronidases Cleavable Linker
β-Galactosidase Cleavable Linker
Sulfatase Cleavable Linker
Chemically Cleavable Linker
Acid Cleavable Linker
Disulfide Linker
Non-Cleavable Linker
ADC Payload Development
Chemical Payload
Microtubule Inhibitors
DNA Damaging Agents
RNA Polymerase Inhibitors
Protein Degraders
Biological Payload
Protein Toxin
Nanocarrier
ADC Manufacturing
ADC cGMP Manufacturing
ADC Fill/Finish
ADC Purification
ADC Formulation Development
ADC Linker–Payload Conjugation
Calicheamicin-Based Linker Conjugation
MMAE/MMAF-Based Linker Conjugation
Deruxtecan-Based Linker Conjugation
SN-38-Based Linker Conjugation
PBD-Based Linker Conjugation
Antibody Modification and Conjugation
Carbohydrate Conjugation
Lysine Conjugation
Enzymatic Conjugation
Cysteine Conjugation
Thio-engineered Antibody
Bispecific Antibody Conjugation
Site-Specific Conjugation
Click Chemistry Conjugation
Non-natural Amino Acids Conjugation
Tyrosine Conjugation
ADC Analysis and Characterization
Drug Distribution Analysis
In Vitro
Analysis
In Vivo
Analysis
ADC Bioanalysis
ADC Bioassay
ADME Analysis
Stability Analysis
DMPK Analysis
Drug-to-Antibody Ratio Analysis
ADC Development Platform
Nanobody-Drug Conjugates (NDCs)
Bispecific Antibody-Drug Conjugates (BsADCs)
Degrader-Antibody Conjugates (DACs)
Antibody Fragment-Drug Conjugates (FDCs)
Scaffold-Drug Conjugates (SDCs)
Dual-Payload Antibody–Drug Conjugates
Targets
HER2 Targets
CD19 Targets
CD22 Targets
CD30 Targets
CD33 Targets
EGFR Targets
CD79b Targets
TF Targets
TROP-2 Targets
BCMA Targets
AXL Targets
c-MET Targets
FOLR1 Targets
Nectin-4 Targets
ROR1 Targets
Solutions
Early Discovery
Process Development
Preclinical Studies
Products
ADC Cytotoxin
Auristatins
Calicheamicins
Camptothecins
Daunorubicins/Doxorubicins
Duocarmycins
Maytansinoids
Piericidins
Pyrrolobenzodiazepines
Traditional Cytotoxic Agents
Other Cytotoxins
ADC Cytotoxin with Linker
ADC Linker
Cleavable Linker
Non-Cleavable Linker
Antibody-Drug Conjugates (ADCs)
Resource
News
Scientific Corner
Frequently Asked Questions
Support Documents
Events
Publications
Company
Contact Us
About Us
Careers
Get A Quote
Home
Resource
Support Documents
Support Documents
Consult with Our Experts
*24/7 customer support, responding within 24 hours of your inquiry.
All
Brochures
Flyer
Posters
ADCs Cytotoxin − Auristatins
ADCs Cytotoxin − Calicheamicins
ADCs Cytotoxin − Camptothecins
ADCs Cytotoxin − Doxorubicins
ADCs Cytotoxin − Duocarmycins
ADCs Cytotoxin − Maytansinoids
ADCs Cytotoxin − Pyrrolobenzodiazepines
ADC Manufacturing Services
Linker Development Services
ADC Conjugation Services
The R&D Barriers of Antibody-drug Conjugates
ADC Analysis and Characterization
ADC Cytotoxin Development
ADC Development for Targets
×
Quick Inquiry
Required fields are marked with *
-
mg
g
kg
ton
Support Documents
We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
SUBMIT
Inquiry Basket
Loading......
Delete selected
Go to checkout
